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Introduction: Recent clinical studies have shown a relationship between abnormalities in peripheral perfusion
and unfavorable outcome in patients with circulatory shock. Nitroglycerin is effective in restoring alterations in
microcirculatory blood flow. The aim of this study was to investigate whether nitroglycerin could correct the
parameters of abnormal peripheral circulation in resuscitated circulatory shock patients.
Methods: This interventional study recruited patients who had circulatory shock and who persisted with abnormal
peripheral perfusion despite normalization of global hemodynamic parameters. Nitroglycerin started at 2 mg/hour
and doubled stepwise (4, 8, and 16 mg/hour) each 15 minutes until an improvement in peripheral perfusion was
observed. Peripheral circulation parameters included capillary refill time (CRT), skin-temperature gradient (Tskin-diff),
perfusion index (PI), and tissue oxygen saturation (StO2) during a reactive hyperemia test (RincStO2). Measurements
were performed before, at the maximum dose, and after cessation of nitroglycerin infusion. Data were analyzed by
using linear model for repeated measurements and are presented as mean (standard error).
Results: Of the 15 patients included, four patients (27%) responded with an initial nitroglycerin dose of 2 mg/hour.
In all patients, nitroglycerin infusion resulted in significant changes in CRT, Tskin-diff, and PI toward normal at the
maximum dose of nitroglycerin: from 9.4 (0.6) seconds to 4.8 (0.3) seconds (P <0.05), from 3.3°C (0.7°C) to 0.7°C
(0.6°C) (P <0.05), and from [log] −0.5% (0.2%) to 0.7% (0.1%) (P <0.05), respectively. Similar changes in StO2 and
RincStO2 were observed: from 75% (3.4%) to 84% (2.7%) (P <0.05) and 1.9%/second (0.08%/second) to 2.8%/second
(0.05%/second) (P <0.05), respectively. The magnitude of changes in StO2 was more pronounced for StO2 of less
than 75%: 11% versus 4%, respectively (P <0.05).
Conclusions: Dose-dependent infusion of nitroglycerin reverted abnormal peripheral perfusion and poor tissue
oxygenation in patients following circulatory shock resuscitation. Individual requirements of nitroglycerin dose to
improve peripheral circulation vary between patients. A simple and fast physical examination of peripheral
circulation at the bedside can be used to titrate nitroglycerin infusion.Introduction
In the early 1960s, the use of vasodilators in shock
started with the interest in flow more than in pressure
[1]. This was followed by clinical observations and some
experimental studies showing the beneficial effects of va-
sodilators in severe (irreversible) shock [2,3]. It took
many years before this topic was the subject of add-
itional experimental studies including new techniques to
monitor the effects of vasodilators [4-9]. These findings* Correspondence: a.pintolima@erasmusmc.nl
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istration of nitroglycerin as a therapeutic approach to
recruit the (sublingual) microcirculation in septic shock
and cardiogenic shock [10-12]. Although these studies
showed that nitroglycerin is effective in restoring abnormal
sublingual microcirculation, the implementation of such a
therapeutic approach in clinical practice is still ham-
pered by technical aspects and complex offline analysis
of the images.
A real-time evaluation of peripheral microcirculatory
disorders would provide bedside assessment for timely
application of nitroglycerin targeting improvement ind. This is an Open Access article distributed under the terms of the Creative
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have demonstrated a significant association between the
persistence of abnormalities in peripheral circulation,
measured in skin, muscle, or sublingual mucosa, with
more severe organ dysfunction and worse prognosis
when compared with traditional global variables of re-
suscitation [13-21]. Although these abnormalities in
peripheral perfusion predict unfavorable outcome in
critically ill patients, it still needs to be proven that these
abnormalities not only can be treated but also result in
improved morbidity or mortality or both. It is reasonable,
therefore, that these fundamental questions ideally be
answered before the introduction of a new monitoring
parameter in clinical practice [22].
Monitoring of peripheral perfusion can be performed
by using simple clinical assessment, in particular, the
physical examination by touching the skin or measuring
capillary refill time (CRT), body temperature gradient, and
optical devices, such as pulse oximeter signal and tissue
oxygen saturation (StO2) [23]. We question whether these
easy, reliable, and robust clinical parameters of peripheral
perfusion can be an effective monitoring approach at the
bedside to titrate the beneficial effects of nitroglycerin.
Therefore, we designed the present study to address two
general hypotheses. First, can nitroglycerin revert abnor-
mal peripheral circulation that persists after initial resusci-
tation in patients with circulatory shock? Second, is there
a dose-dependent effect that would require individuali-
zation of the nitroglycerin dose?
Materials and methods
Setting and participants
This was an intervention study within the intensive care
unit (ICU) of a university hospital. The local accredited
Medical Research Ethical Committee from Erasmus MC
Hospital approved the study. Written informed consent
was obtained from all patients, their next of kin, or a
surrogate decision maker, as appropriate. All consecutive
patients admitted in the ICU for circulatory shock resus-
citation were eligible for inclusion. Circulatory shock was
defined as hypotension (systolic blood pressure of less
than 90 mm Hg, mean arterial pressure of less than
70 mm Hg, or a systolic blood pressure decrease of greater
than 40 mm Hg below normal range), despite adequate
fluid resuscitation or the requirement for continuous nor-
epinephrine infusion, and the presence of metabolic acid-
osis (arterial pH of less than 7.35 or base excess of less
than −3 mmol/L) in association with increased lactate
levels (>2 mmol/L). Patients were eligible for inclusion if,
after 6 hours of ICU admission and continuous resuscita-
tion and stabilization, abnormal peripheral perfusion was
still present despite normalization of global hemodynamic
parameters. Accordingly, all patients included shared abnor-
malities in peripheral perfusion as baseline characteristics.Exclusion criteria were arm injury or ischemia from trauma
(disturbing measurement of peripheral circulation), liver
failure, and any neurological insult that could lead to
increased intracranial pressure (stroke, subarachnoid he-
morrhage, or brain trauma injury).
Measurements
All patients were monitored with a radial artery catheter
for continuous arterial pressure monitoring. Global hemo-
dynamic variables included heart rate, central venous
pressure, and mean arterial pressure. All measurements
were obtained by using standard equipment. Cardiac out-
put was obtained if the patient was monitored with con-
tinuous pulse contour cardiac analysis (PiCCO; Pulsion
Medical Systems AG, Munich, Germany).
Peripheral circulation parameters included physical
examination of peripheral perfusion with CRT, forearm-
to-fingertip skin-temperature gradient (Tskin-diff ), and
peripheral perfusion index (PI) from pulse oximeter signal.
CRT was measured by applying firm pressure to the distal
phalanx of the index finger for 15 seconds. A chronometer
recorded the time for the return of normal color, and
5 seconds was defined as the upper limit of normality
[24]. Tskin-diff was obtained with two skin probes
(Hewlett-Packard 21078A; Hewlett-Packard, Palo Alto,
CA, USA) attached to the index finger and on the radial
side of the forearm, midway between the elbow and the
wrist. Tskin-diff can better reflect changes in cutaneous
blood flow than skin temperature itself. When evaluated
under constant environmental conditions, Tskin-diff in-
creases during vasoconstriction, and a threshold of 2°C
has been shown to reflect vasoconstriction in critically ill
patients [25,26]. Peripheral PI provides a non-invasive
method for evaluating perfusion and has been shown to
reflect changes in peripheral circulation [27]. In this study,
the peripheral PI value was obtained by using a pulse
oximeter (Masimo® SET Radical-7; Masimo Corporation,
Irvine, CA, USA), which displays a range from 0.02% (very
weak pulse strength) to 20.0% (very strong pulse strength).
In addition, we used near-infrared spectroscopy for StO2-
derived tissue oxygenation measurements to investigate
the dynamic changes between tissue oxygenation and con-
dition of peripheral perfusion. StO2-derived tissue oxygen-
ation was monitored continuously by using an InSpectra
Tissue Spectrometer Model 650 (Hutchinson Technology
Inc., Hutchinson, MN, USA) with a 15-mm probe over
the thenar eminence. A vascular occlusion test was perfor-
med by arrest of forearm blood flow by using a conven-
tional sphygmomanometer pneumatic cuff. The cuff was
placed around the upper arm and was inflated to a pres-
sure approximately 30 mm Hg greater than patient
systolic pressure for 3 minutes. Upon completion of the
ischemic period, the occluding cuff was rapidly deflated to
0 mm Hg. The derived StO2 parameters were divided into
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uration (RdecStO2, expressed as percentage per minute),
and rate of StO2 recovery (RincStO2, expressed as percen-
tage per second).
Patients were considered to have abnormal peripheral
circulation if the examined extremities (both hands) had
an increase in CRT of greater than 5 seconds or indicated
the presence of peripheral vasoconstriction (Tskin-diff of
greater than 2°C and peripheral PI of less than 1.4%). The
ICU has single-patient closed rooms, and the ambient
temperature in each room was individually and actively
set at 22°C.
Study design
To avoid significant hypotension during nitroglycerin
infusion, each patient was evaluated for adequate intravas-
cular volume as evidenced by repeated volume challenges
(250 mL of crystalloid over 10 minutes) up to a point at
which central venous pressure raised by more than 2 mm
Hg or stroke volume did not increase more than 10%.
After documentation of central venous pressure or stroke
volume changes, a set of measurements was obtained dur-
ing a control period. After baseline measurements, nitro-
glycerin was given as a bolus equal to the volume of the
used infusion line followed by a continuous intravenous
infusion initiated at 2 mg/hour (33.3 μg/minute). When
peripheral circulation did not normalize within 15 minutes
after the start of the nitroglycerin infusion, repeated mea-
surements of hemodynamic and peripheral perfusion
parameters were recorded and the dose was doubled. This
was repeated until peripheral perfusion was normalized or
a dose of 16 mg/hour was reached (Figure 1). The step-
wise increase in nitroglycerin infusion rate resulted in the
following dosages used: 4 mg/hour (66.6 μg/minute), 8 mg/
hour (133.3 μg/minute), and 16 mg/hour (266.6 μg/mi-
nute). We defined improvement in peripheral perfusion as
a change of more than 50% in baseline parameters of CRT
or the presence of peripheral vasodilation (Tskin-diff of less
than 2°C or peripheral PI of greater than 1.4%). At the end
of the stepwise increase in nitroglycerin when peripheral
circulation was corrected and a final set of measurementsFigure 1 Flowchart of the study protocol. Time points of the study wer
when peripheral perfusion was normalized at the maximum dose of nitrog
nitroglycerin infusion (TBL2). NTG, nitroglycerin.had been made, the infusion of nitroglycerin was stopped.
A second set of baseline measurements was recorded
30 minutes after cessation of the infusion (Figure 1).
The nitroglycerin infusion was stopped if the patient
developed significant hypotension (mean arterial pressure
of less than 50 mm Hg). During the study, infusion rates of
noradrenaline or other vasoactive drugs were not changed
and no additional fluids were administered.
Statistical analysis
Unless otherwise specified, descriptive analyses are repor-
ted as median (25th-75th). Time points of the study were
defined as TBL1 (baseline before nitroglycerin infusion),
TMX (at the maximum dose of nitroglycerin), and TBL2
(30 minutes after cessation of nitroglycerin infusion). We
used a Kolmogorov-Smirnov test and stratified distribution
plots to verify the normality of distribution of continuous
variables. Not normally distributed data underwent log
transformation to achieve close to normal distribution
and then qualified for longitudinal testing. We used
linear model for repeated measurements (time points
as independent factor) to investigate changes in the aver-
age of hemodynamic and peripheral perfusion parameters
(dependent variables). The analyses of linear model are
reported as mean response (standard error). Differences
between groups’ means were tested by Mann-Whitney U
test. A multiple regression analysis was applied to estimate
the effect of nitroglycerin dose (independent variable) on
parameters of peripheral perfusion (dependent variables)
so that we could predict changes in CRT, Tskin-diff, per-
ipheral PI, and StO2 for a given nitroglycerin dose. SPSS
(version 15.0; SPSS, Inc., Chicago, IL, USA) was used for
statistical analysis. A P value of less than 0.05 was consid-
ered statistically significant.
Results
Of the 15 patients included in the study, 12 had septic
shock and three had non-septic shock. Patients’ demo-
graphic data are summarized in Table 1. At the moment
of inclusion (6 hours after ICU admission), all patients
had central venous oxygen saturation of at least 70% ande defined as baseline 1 before nitroglycerin infusion (TBL1), time point
lycerin (TMX), and baseline 2 recorded 30 minutes after cessation of
Table 1 Baseline characteristics of the patients
Patient demographic data
Number of patients 15
Age, years 63 (48-71)
Male/Female 9/6
SOFA score 10 (5-11)
APACHE II score 22 (16-27)





Noradrenaline use, number (percentage) 14 (93%)
Noradrenaline dose, μg/kg per minute 0.13 (0.03-0.40)
Mechanical ventilation, number (percentage) 15 (100%)
Lactate, mmol/L 1.8 (1.1-2.1)
Survivor/Non-survivor 10/5
Values are expressed as median (25th-75th) except where indicated otherwise.
APACHE II, Acute Physiology and Chronic Health Evaluation II; SOFA,
Sequential Organ Failure Assessment.
Table 3 Peripheral perfusion parameters recorded in the
three different time points during execution of the study
protocol (n = 15)
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2.0 mmol/L). The total amount of volume for fluid chal-
lenge necessary for each patient was 416 ± 204 mL. As the
protocol was based on dose response, some patients had
longer durations of nitroglycerin infusion than others. In
only four patients (27%), nitroglycerin infusion response
was observed with the initial dose of 2 mg/hour. In two
patients, the highest dose of nitroglycerin (16 mg/hour)
was necessary to improve peripheral perfusion; five pa-
tients required 4 mg/hour, and four patients required
8 mg/hour. Table 2 shows the hemodynamic effects of
nitroglycerin infusion during execution of the study
protocol stratified by the time points. In all patients,
mean arterial pressure was significantly lower at theTable 2 Global hemodynamic variables recorded in the
three different time points during execution of the study
protocol (n = 15)
TBL1 TMX TBL2
Heart rate, beats per minute 95 (4.3) 97 (4.4) 98 (4.4)
Systolic blood pressure, mm Hg 113 (4.6) 94 (4.0)a 111 (3.8)a
Diastolic blood pressure, mm Hg 52 (4.9) 49 (4.8)a 57 (4.9)a
Mean arterial blood pressure, mm Hg 75 (3.0) 61 (2.9)a 71 (2.3)a
Central venous pressure, mm Hg 12 (4.0) 9 (5.0)a 10 (6.0)
Cardiac index, n = 6, L/min per m2 4.1 (0.4) 3.8 (0.5) 3.9 (0.4)
Stroke volume, n = 6, mL 78 (15) 66 (14) 77 (12)
Data are presented as mean (standard error). aP <0.05 versus previous time
point (linear model for repeated measurements). Time points are defined as
before nitroglycerin infusion (TBL1), at the maximum dose of nitroglycerin
(TMX), and 30 minutes after cessation of nitroglycerin (TBL2). Cardiac index and
stroke volume were measured in six patients.maximum-dose time point (TMX). Cardiac index and
stroke volume were measured in six patients; although
both parameters showed a slight decrease, no significant
differences were observed during nitroglycerin infusion.
Baseline parameters of peripheral perfusion and the
effects of nitroglycerin on these parameters are shown in
Table 3. Two patients did not tolerate the 3-minute vas-
cular occlusion test and therefore neither RincStO2 nor
RdecStO2 is reported for these patients. Improvement in
peripheral perfusion was reached in all patients. All 15
patients responded with more than 50% of CRT and PI
of greater than 1.4% at the maximum dose of nitrogly-
cerin, and nine patients responded additionally with
Tskin-diff of less than −2. Twelve patients required a
low dose of nitroglycerin (of less than 8 mg/hour) to
normalize the peripheral perfusion parameters. We did
not find differences in CRT, PI, and Tskin-diff at baseline
between patients requiring low doses and patients requir-
ing high doses. Therefore, all patients included shared
abnormalities in peripheral perfusion before nitroglycerin
infusion. Figure 2 shows the time course of peripheral per-
fusion parameters for each patient during nitroglycerin
infusion at TBL1, TMX, and TBL2. Nitroglycerin infusion re-
sulted in significant changes in CRT, Tskin-diff, and per-
ipheral PI toward normal compared with baseline values:
51% (50% to 44%), 85% (30% to 112%), and 178% (105% to
295%), respectively. Similarly, we observed a significant
increase in StO2 and RincStO2 values but not in RdecStO2
at TMX. All parameters returned to baseline values after
cessation of nitroglycerin infusion.
Table 4 shows estimates from multiple regression analysis
with respective confidence intervals predicting changes in
CRT, Tskin-diff, peripheral PI, and StO2 for a givenTBL1 TMX TBL2
Capillary refill time, seconds 9.4 (0.6) 4.8 (0.3)a 7.1 (0.8)a
Tskin-diff, degrees Celsius 3.3 (0.7) 0.7 (0.6)a 1.8 (0.6)a
PI.log, percentage −0.5 (0.2) 0.7 (0.1)a 0.2 (0.1)a




11.1 (1.3) 13.2 (1.4)a 11.6 (1.2)a
RincStO2, n = 13, percentage
per second
1.9 (0.08) 2.8 (0.05)a 2.4 (0.09)a
RdecStO2, n = 13, percentage
per minute
8.6 (0.5) 9.2 (0.6) 9.14 (0.7)
Data are presented as mean (standard error). aP <0.05: previous time point
(linear model for repeated measurements). Time points are defined as before
nitroglycerin infusion (TBL1), at the maximum dose of nitroglycerin (TMX), and
30 minutes after cessation of nitroglycerin (TBL2). Rate of tissue oxygen
saturation increase after arterial occlusion (RincStO2) and rate of tissue oxygen
saturation deoxygenation during arterial occlusion (RdecStO2) were collected
from 13 patients. PI, perfusion index; Tskin-diff, forearm-to-fingertip
skin-temperature gradient.
Figure 2 Temporal behavior of peripheral circulation parameters (CRT, Tskin-diff, and PI) and StO2-derived variables (StO2, RincStO2,
and RdecStO2) during study protocol. Time points are defined as before nitroglycerin infusion (TBL1), at the maximum dose of nitroglycerin
(TMX), and 30 minutes after cessation of nitroglycerin (TBL2). CRT, capillary refill time (seconds); PIlog, log of perfusion index (percentage); RdecStO2,
rate of peripheral tissue oxygenation desaturation during arterial occlusion (percentage per minute); RincStO2, rate of peripheral tissue oxygenation
recovery after arterial occlusion (percentage per second); StO2, peripheral tissue oxygenation (percentage); Tskin-diff, forearm-to-fingertip
skin-temperature gradient (degrees Celsius). Lines represent individual values for each patient. Bars are mean ± 95% confidence interval (CI).
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dose had a significant effect on CRT, Tskin-diff, and periph-
eral PI but not on StO2. When StO2 baseline values before
nitroglycerin infusion were taken into account, the effect of
changes in nitroglycerin dose becomes clearly significant.
The magnitude of changes in StO2 was more prominent at
lower StO2 values (Figure 2). Compared with baseline,
patients with StO2 of less than 75% at TBL1 had a bigger
response than patients with StO2 of greater than 75%: 10%
(9.0% to 11.1%) versus 7% (4.7% to 10.5%) (P <0.05).
Discussion
We have demonstrated that intravenous infusion of nitro-
glycerin improves peripheral perfusion and oxygenation inTable 4 Estimation of the effect of nitroglycerin dose on
all parameters of peripheral perfusion
Estimate 95% CI P value
Constant 8.9 4.60, 13.10 0.001
Capillary refill time, seconds −0.91 −1.10, −0.50 0.001
Tskin-diff, degrees Celsius 0.35 0.09, 0.61 0.008
Perfusion index, percentage 1.2 0.55, 1.85 0.001
StO2, percentage −0.02 −0.07, 0.03 0.42
StO2, percentage, corrected
for baseline StO2
0.30 0.14, 0.47 0.001
CI, confidence interval; StO2, tissue oxygen saturation; Tskin-diff, forearm-to-
fingertip skin temperature gradient.shock patients with persisting abnormal peripheral cir-
culation following initial resuscitation to global hemody-
namic endpoints. Although nitroglycerin is generally used
for its cardio-circulatory effects, its precise application in
septic or non-septic circulatory shock continues to be
debated and investigated. The use of vasodilators in shock
was introduced into the clinic in the early 1960s as an
additional therapeutic option for circulatory shock with or
without cardiac dysfunction to counteract peripheral
vasoconstriction [1,2,28]. However, the concept of using
vasodilator therapy to target microcirculatory flow in
critically ill patients originated in the 1990s with clinical
trials of different types of vasodilators (prostacyclin and
N-acetylcysteine) targeting splanchnic perfusion as assessed
by gastric tonometry [29-32]. These studies demonstrated
an improvement in gastric perfusion with vasodilator ad-
ministration suggesting successful microcirculatory recruit-
ment. More recently, with the advent of video microscopy
techniques allowing direct visualization of the (sublingual)
microcirculation, some studies have evaluated short-term
infusions of nitroglycerin in septic or non-septic shock and
demonstrated significant improvements in capillary perfu-
sion [10-12]. In a randomized controlled trial in 70 patients
with septic shock, Boerma and colleagues [11] failed to
show significant differences in the evolution of the sublin-
gual microcirculation between the control and nitroglycerin
groups. Although this study precluded the effectiveness of
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fixed dose of nitroglycerin used (2 mg/hour) was able to
significantly increase skin blood flow as measured by
central-to-toe temperature gradient in the treatment group.
In addition to that finding, the authors reported lower
Sequential Organ Failure Assessment (SOFA) scores in
patients who received nitroglycerin compared with the
placebo group. In our study, a dose of 2 mg/hour was not
sufficient to improve peripheral perfusion in almost 80%
of the patients, indicating that the nitroglycerin dose aim-
ing to normalize abnormal peripheral perfusion should be
individualized. In addition, since its dose-dependent effect
can be easily predicted (Table 4) and the parameters of
abnormal peripheral circulation can be easily obtained at
the bedside, the use of nitroglycerin to correct an abnor-
mal peripheral circulation can be easily implemented in
clinical practice.
The persistent abnormalities in peripheral circulation
have been shown to predict a poor outcome in critically
ill patients in terms of mortality and multiple organ
dysfunction [13-15,18,20,33]. To what extent peripheral
perfusion parameters result in abnormal vital organ dys-
function causing these reported increases in morbidity
and mortality is currently speculative. Nevertheless, the
true clinical usefulness of peripheral perfusion monitoring
can be supported only if it can be used to guide therapy to
change outcome. Studies have shown that resuscitation
procedures aiming at supporting global perfusion fail to
normalize peripheral perfusion [34]. Therefore, more spe-
cific direct interventions to correct abnormalities in
peripheral perfusion, such as a vasodilator, would be a
first step to meet this resuscitation goal. The rationale
of vasodilator therapy is based on the concept that blood
flow in the peripheral circulation is regulated by changes
in perfusion pressure, which is determined by intravas-
cular pressure gradient and vessel radius of arterial
peripheral circulation. Although the vessel radius has
an important effect on flow (fourth power of the radius),
the flow occurs only if there is a difference of pressure
[35]. Microcirculatory perfusion pressure is, therefore, the
net result of precapillary inflow pressure minus venular
outflow pressure. From this physiologic perspective, a
series of clinical studies have assessed the effect of vasodi-
lators as potential adjunctive therapy to recruit micro-
vascular perfusion in circulatory shock [10-12,29-32,36].
Nitroglycerin has some attributes that favor its use to
recruit the microcirculation in critically ill patients. First,
nitroglycerin has a quick onset of action (2 to 5 minutes)
with a half-life elimination of 1 to 3 minutes. Second,
nitroglycerin has specific hemodynamic effects in the
venous capacitance vessels resulting in pressure gradient
increase in the microvasculature and thus in microvascu-
lar blood flow. In this study, improvements in the clinical
parameters of peripheral circulation were obtained in allpatients. CRT improved in parallel with changes in Tskin-
diff and peripheral PI, suggesting that the improvement in
cutaneous circulation was likely the result of an increase
in cutaneous blood flow. As the major role of cutaneous
circulation is thermoregulation, blood flow to the skin typ-
ically exceeds metabolic requirements. Therefore, the high
blood flow relative to its oxygen demand makes the skin
an appropriate organ to detect variations in peripheral
blood flow.
Another interesting finding in our study was that nitro-
glycerin infusion led to a significant improvement in per-
ipheral tissue oxygenation. In addition, the magnitude of
changes in StO2 was more pronounced in patients who
had lower StO2 values (less than 75%). This finding may
be explained by the shift of blood volume from arterial to
venous compartment because of predominant venous
dilation with a subsequent increase in the oxyhemoglobin
levels within the volume of the vascular bed in the catch-
ment area of the near infrared spectroscopy (NIRS) probe.
Significant gain in StO2 is, therefore, observed in condi-
tions in which the functional microcirculatory reserve is
poor, such as those seen in abnormal peripheral circula-
tion. In these conditions, a low initial StO2 value yields a
greater percentage change. Alternatively, we found parallel
changes in StO2 reoxygenation rate but not in the StO2
deoxygenation rate. Unlike the StO2 deoxygenation rate
during arterial occlusion in which venous outflow and
arterial inflow are blocked, StO2 recovery after the vascu-
lar occlusion reflects the sudden increase of arterial inflow
during the hyperemic response. Infusing a vasodilator will
result in a larger flow-mediated dilation following reactive
hyperemia and therefore in a higher rate of reoxygenation.
This pattern of changes in tissue oxygenation parameters
is consistent with previous reports, including some of our
own group, showing that StO2-derived parameters are
influenced by peripheral vasoregulation [37-40]. Given
that oxygen demand remained unchanged as reflected by
constant StO2 deoxygenation rate in our patients, any in-
crease in flow would result in an increase in microcircula-
tory hemoglobin saturation levels. Thereby, the noticeable
changes in StO2 and StO2 recovery rate in our patients
provide evidence that nitroglycerin markedly improves
tissue oxygenation.
Although this study makes novel observations, a limita-
tion to our study is the small number of patients. Despite
this sample size, our patients shared the same baseline
common abnormality in peripheral perfusion, and our
study was designed to allow every patient to serve as his
or her own control, thereby minimizing bias. Hence, the
evident significant improvement and worsening in the
clinical parameters of peripheral circulation in all patients
during and after nitroglycerin infusion strengthen our
findings. Another important point to mention is that the
effect of nitroglycerin on skin and muscle perfusion as
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organs, such as gastrointestinal tract, liver, or kidneys.
However, the accumulating evidence from the literature
supports the efficacy of vasodilator therapy in improving
microcirculatory perfusion in these different vascular beds.
We speculate, therefore, that nitroglycerin infusion in our
patients had the same beneficial effect as seen in the per-
ipheral tissues. Finally, our study supports the hypothesis
that nitroglycerin dose should be individualized and shows
that non-invasive and rapidly available measures of per-
ipheral circulation at the bedside are available to predict
its response and monitor the effect to reach an effective
dose (Table 4). However, an important next step before
the introduction of monitoring peripheral circulation and
its treatment with individualized dose of nitroglycerin
should be a randomized clinical trial showing clinical
benefit for critically ill patients with persistent abnormal
peripheral perfusion.
Conclusions
We demonstrated with this study that stepwise dose of
intravenous infusion of nitroglycerin reverses clinical
abnormalities of peripheral circulation in patients with
circulatory shock. In addition, we showed that the easy
and reliable clinical parameters of peripheral perfusion
can be an effective monitoring approach at the bedside
to titrate the beneficial effects of nitroglycerin on periph-
eral circulation in individual patients with circulatory
shock following initial resuscitation.
Key messages
 Stepwise dose of intravenous infusion of
nitroglycerin reverses clinical abnormalities
of peripheral circulation in patients with
circulatory shock.
 Nitroglycerin infusion response in some
patients was observed with the dose higher
than the conventional dose of 2 mg/hour.
 The easy and reliable clinical parameters of
peripheral perfusion can be an effective monitoring
approach at the bedside to titrate the beneficial
effects of nitroglycerin on microcirculation in
individual patients with circulatory shock following
initial resuscitation.
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